Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Antibacterial drug discovery & development summit.

John F Barrett¹, Thomas J Dougherty

¹Merck Research Laboratories, Rahway, NJ, USA. John_barrett2@merck.com

Expert Opinion on Investigational Drugs

|June 4, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibacterial and mechanism of action studies of boxazomycin A.

The Journal of antibiotics·2024

Same author

Transcriptional Responses of Pseudomonas aeruginosa to Inhibition of Lipoprotein Transport by a Small Molecule Inhibitor.

Journal of bacteriology·2020

Same author

Correct Sorting of Lipoproteins into the Inner and Outer Membranes of Pseudomonas aeruginosa by the Escherichia coli LolCDE Transport System.

mBio·2019

Same author

Transcriptional Responses of Escherichia coli to a Small-Molecule Inhibitor of LolCDE, an Essential Component of the Lipoprotein Transport Pathway.

Journal of bacteriology·2016

Same author

Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box.

Current opinion in microbiology·2016

Same author

Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay.

Journal of bacteriology·2015

Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026

Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026

Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026

Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026

Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026

Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026

See all related articles

Senior researchers convened at an international summit on antibacterial research and development (R&D). Biotechnology firms showcased advancing compounds, while basic research explored novel targets and mechanisms.

Area of Science:

* Antimicrobial resistance research and development.
* Biotechnology and pharmaceutical industry collaborations.
* Academic and industrial research partnerships.

Background:

* Focus on the critical need for novel antibacterial agents.
* Addressing the global challenge of antimicrobial resistance (AMR).
* Annual international discovery summit format.

Framework:

* Presentation of compounds in clinical development pipelines.
* Exploration of fundamental research areas.
* Collaborative R&D framework.

Implementation:

* Biotechnology firms presented novel antibacterial compounds.
* Discussions on advancing compounds through clinical trials.
* Identification of key areas for basic research.

Related Experiment Videos

Implications:

* Accelerated development of new antibacterial therapies.
* Strengthened collaboration between academia and industry.
* Enhanced understanding of AMR mechanisms and potential targets.